Cetuximab: A standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck

Oncology Reviews

Volumn 3, Issue 4, 2009, Pages 247-256

  Bernier, Jacques ^a  

^a Genolier Swiss Medical Network SA   (Switzerland)

Author keywords

Cetuximab; Head and neck; Locally advanced; Recurrent and or metastatic; Squamous cell carcinoma

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

ADVANCED CANCER; ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; HEAD AND NECK CARCINOMA; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SEPSIS; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA;

EID: 70450263408     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-009-0026-3     Document Type: Review

References (54)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078
2. J Ferlay P Autier M Boniol, et al. 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 581 592 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D 17287242 (Pubitemid 46359643)
3. BD Smith GL Smith A Hurria, et al. 2009 Future of cancer incidence in the United States: burdens upon an aging, changing nation J Clin Oncol 27 2758 2765 10.1200/JCO.2008.20.8983 19403886
4. RI Nicholson JM Gee ME Harper 2001 EGFR and cancer prognosis Eur J Cancer 37 Suppl 4 S9 S15 10.1016/S0959-8049(01)00231-3 1:CAS:528:DC%2BD3MXntlOku7w%3D 11597399
5. ME Christensen MH Therkildsen BL Hansen, et al. 1992 Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas Eur Arch Otorhinolaryngol 249 243 247 10.1007/BF00714485 1:STN:280:DyaK38zpvV2gsw%3D%3D 1524803
6. JR Grandis MF Melhem EL Barnes DJ Tweardy 1996 Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck Cancer 78 1284 1292 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID- CNCR17>3.0.CO;2-X 1:CAS:528:DyaK28XlvVCquro%3D (Pubitemid 26303896)
7. RS Herbst DM Shin 2002 Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy Cancer 94 1593 1611 10.1002/cncr.10372 1:CAS:528:DC%2BD38XisVWmtb8%3D 11920518 (Pubitemid 34212655)
8. L Licitra E Felip 2009 Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl 4 121 122 19454430
9. EE Cohen MW Lingen EE Vokes 2004 The expanding role of systemic therapy in head and neck cancer J Clin Oncol 22 1743 1752 10.1200/JCO.2004.06.147 15117998 (Pubitemid 41079815)
10. AA Forastiere B Metch DE Schuller, et al. 1992 Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study J Clin Oncol 10 1245 1251 1:STN:280: DyaK38zktFWguw%3D%3D 1634913
11. J Lokich N Anderson 1998 Carboplatin versus cisplatin in solid tumors: an analysis of the literature Ann Oncol 9 13 21 10.1023/A:1008215213739 1:STN:280:DyaK1c3gt1Omuw%3D%3D 9541678 (Pubitemid 28125759)
12. M Benasso A Ponzanelli M Merlano, et al. 2006 Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group Acta Oncol 45 168 174 1:CAS:528:DC%2BD28Xis1CitL0%3D 16546862
13. FP Worden J Moon W Samlowski, et al. 2006 A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007 Cancer 107 319 327 10.1002/cncr.21994 1:CAS:528:DC%2BD28Xnsl2mtLg%3D 16779801 (Pubitemid 44036561)
14. B Burtness MA Goldwasser W Flood, et al. 2005 Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study J Clin Oncol 23 8646 8654 10.1200/JCO.2005.02.4646 16314626 (Pubitemid 46211507)
15. J Bourhis F Rivera R Mesia, et al. 2006 Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 24 2866 2872 10.1200/JCO.2005.04.3547 1:CAS:528:DC%2BD28XntV2gsrk%3D 16717293 (Pubitemid 46630587)
16. JB Vermorken R Mesia F Rivera, et al. 2008 Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 1116 1127 10.1056/NEJMoa0802656 1:CAS:528:DC%2BD1cXhtFWrsrnI 18784101
17. C Jacobs G Lyman E Velez-Garcia, et al. 1992 A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck J Clin Oncol 10 257 263 1:STN:280:DyaK387itF2gtA%3D%3D 1732427
18. MK Gibson Y Li B Murphy, et al. 2005 Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group J Clin Oncol 23 3562 3567 10.1200/JCO.2005.01.057 1:CAS:528: DC%2BD2MXlsVyhs78%3D 15908667 (Pubitemid 46243501)
19. Hitt R, Irigoyen A, Nuñez J et al (2007) Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC). J Clin Oncol 25(18S):Abstract 6012. Virtual presentation http://www.asco.org
20. Baselga J, Trigo JM, Bourhis J et al (2005) Phase ll multicenter study of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 23:5568-5577
21. Buentzel J, de Vries A, Micke O (2007) Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer. J Clin Oncol 25(18S):Abstract 6077 (updated information presented at meeting)
22. RS Herbst M Arquette DM Shin, et al. 2005 Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck J Clin Oncol 23 5578 5587 10.1200/JCO.2005.07.120 1:CAS:528:DC%2BD2MXhtVersr%2FK 16009949 (Pubitemid 46300152)
23. Knoedler MK, Gauler T, Matzdorff A et al (2009) Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN. J Clin Oncol 27(15S):Abstract 6048
24. Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171-2177
25. DJ Adelstein Y Li GL Adams, et al. 2003 An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer J Clin Oncol 21 92 98 10.1200/JCO.2003.01.008 12506176
26. JP Pignon A le Maitre J Bourhis 2007 Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update Int J Radiat Oncol Biol Phys 69 S112 S114 17848275
27. TG Wendt GG Grabenbauer CM Rodel, et al. 1998 Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study J Clin Oncol 16 1318 1324 1:STN:280: DyaK1c3htFOmug%3D%3D 9552032
28. M Machtay J Moughan A Trotti, et al. 2008 Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis J Clin Oncol 26 3582 3589 10.1200/JCO.2007.14.8841 1:CAS:528:DC%2BD1cXpvVWmtLc%3D 18559875
29. A Eisbruch 2007 Commentary: induction chemotherapy for head and neck cancer: hypothesis-based rather than evidence-based medicine Oncologist 12 975 977 10.1634/theoncologist.12-8-975 17766657 (Pubitemid 47359140)
30. MR Posner DM Hershock CR Blajman, et al. 2007 Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 1705 1715 10.1056/NEJMoa070956 1:CAS:528:DC%2BD2sXht1ansLvI 17960013 (Pubitemid 350005152)
31. JB Vermorken E Remenar C van Herpen, et al. 2007 Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 1695 1704 10.1056/NEJMoa071028 1:CAS:528:DC%2BD2sXht1ansLvP 17960012 (Pubitemid 350005151)
32. (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690
33. JA Bonner PM Harari J Giralt, et al. 2006 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 567 578 10.1056/NEJMoa053422 1:CAS:528:DC%2BD28Xhtleksbs%3D 16467544 (Pubitemid 43209104)
34. Bonner JA, Harari PM, Giralt J et al (2008) Prolongation of survival with the addition of cetuximab to radiation in patients with locoregionally advanced head and neck cancer (SCCHN): five-year results from a randomized trial. ASTRO, Boston, MA, USA, 19-25 September
35. JJ Caudell SM Sawrie SA Spencer, et al. 2008 Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment Int J Radiat Oncol Biol Phys 71 678 681
36. C Giro B Berger E Bolke, et al. 2009 High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes Radiother Oncol 90 166 171 10.1016/j.radonc.2008.09.007 1:CAS:528:DC%2BD1MXhvFGkt7o%3D 18977050
37. DI Pryor SV Porceddu BH Burmeister, et al. 2009 Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer Radiother Oncol 90 172 176 10.1016/j.radonc.2008.09.018 1:CAS:528:DC%2BD1MXhvFGkt7s%3D 18976827
38. J Bernier J Bonner JB Vermorken, et al. 2007 Consensus guidelines for the management of radiation dermatitis and co-existing acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck Ann Oncol 19 142 149 10.1093/annonc/mdm400 17785763
39. Lefebvre JL, Pointreau Y, Rolland F et al. (2009) Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study. J Clin Oncol 27(15S):Abstract 6010
40. N Zhang K Erjala J Kulmala, et al. 2009 Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro Radiother Oncol 92 388 392 10.1016/j.radonc.2009.04.019 1:CAS:528: DC%2BD1MXhtFajtL%2FO 19447510
41. Argiris AE, Gibson MK, Heron DE et al (2008) Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer (HNC). J Clin Oncol 26:Abstract 6002. Virtual presentation http://www.asco.org
42. Langer CJ, Lee JW, Patel AU et al (2008) Preliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 26:Abstract 6006. Virtual presentation http://www.asco.org
43. Tishler RB, Posner MR, Wirth LJ et al (2008) Cetuximab added to docetaxel, cisplatin, 5-fluorouracil induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol 26:Abstract 6001
44. Vermorken JB, Mesia R, Remenar E et al (2008) Predictors of efficacy in the EXTREME study: cetuximab plus platinum-based therapy first-line in patients with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 19(Suppl 8):Abstract 687O (updated information presented at the meeting)
45. JA Anderson JC Irish BY Ngan 1992 Prevalence of RAS oncogene mutation in head and neck carcinomas J Otolaryngol 21 321 326 1:STN:280:DyaK3s7gvVCqtg%3D%3D 1361585
46. IO Rathcke S Gottschlich T Gorogh, et al. 1996 Incidence of point mutations in Ki-ras codon 12 and 13 in squamous epithelial carcinomas of the head-neck region Laryngorhinootologie 75 465 470 10.1055/s-2007-997616 1:STN:280:DyaK28vjslKksQ%3D%3D 8962608
47. A Italiano P Follana FX Caroli, et al. 2008 Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number Ann Surg Oncol 15 649 654 10.1245/s10434-007-9667-2 17987340
48. Licitra L, Rolland F, Bokemeyer C et al (2009) Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: platinum-based CT + cetuximab in 1st-line R/M SCCHN. J Clin Oncol 27(15S):Abstract 6005
49. LS Elting DM Keefe ST Sonis, et al. 2008 Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life Cancer 113 2704 2713 10.1002/cncr.23898 18973181
50. AP Jellema BJ Slotman P Doornaert, et al. 2007 Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer Int J Radiat Oncol Biol Phys 69 751 760 17560735
51. LQ Rogers K Rao J Malone, et al. 2009 Factors associated with quality of life in outpatients with head and neck cancer 6 months after diagnosis Head Neck 31 1207 1214 10.1002/hed.21084 19360748
52. MW El-Deiry ND Futran JA McDowell, et al. 2009 Influences and predictors of long-term quality of life in head and neck cancer survivors Arch Otolaryngol Head Neck Surg 135 380 384 10.1001/archoto.2009.18 19380361
53. Rivera Herrero F, Hitt R, Kawecki A et al (2008) Cetuximab plus platinum-based therapy first-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: a quality of life (QOL) analysis of the EXTREME trial. Ann Oncol 19(Suppl 8):Abstract 693PD (updated information presented at meeting)
54. D Curran J Giralt PM Harari, et al. 2007 Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab J Clin Oncol 25 2191 2197 10.1200/JCO.2006.08.8005 1:CAS:528:DC%2BD2sXnsVSht7c%3D 17538164 (Pubitemid 46954642)